Trial Information

Summary: A Study of MabThera (Rituximab) in Combination With a Chemotherapy Regimen for the Treatment of Chronic Lymphocytic Leukemia.

Status: No longer recruiting

Protocol Number: ML17102

Sponsor: F Hoffman-La Roche Ltd

Company Division: Pharmaceutical

Official Scientific Title: A randomized, open-label study of the effect of MabThera, with and without fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia

Brief Summary: This study will assess the efficacy and safety of adding MabThera to chemotherapy in patients with previously untreated B-cell chronic lymphocytic leukemia (B-CLL). The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals. Target sample size is 760.

Study Phase: III

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Randomized
  • Masking: Open Label
  • Control: Active
  • Assignment: Parallel
  • Endpoints: Safety/Efficacy

Study Type:

Interventional

Condition: Lymphocytic Leukemia, Chronic

Intervention Type: Drug

Intervention Name: rituximab[MabThera/Rituxan]

Primary Outcome: 1. Progression-free survival

Key Secondary Outcomes: 1. Event-free survival; overall survival; disease-free survival; duration of remission; time to new CLL treatment or death; rates of molecular, complete, and partial remission; treatment-related adverse events; pharmacoeconomic impact; QOL

Inclusion Criteria:

  • adult patients >=18 years of age;
  • confirmed B-CLL;
  • no previous chemotherapy, radiotherapy, or immunotherapy for the treatment of CLL;
  • women of childbearing potential must have a negative serum pregnancy test 7 days prior to treatment, and must be prepared to use reliable contraception for the duration of treatment, and for 2 months after the end of treatment.

Exclusion Criteria:

  • women who are pregnant or lactating;
  • active secondary malignancy currently requiring treatment;
  • transformation to aggressive B-cell malignancy.

Gender: Males or Females

Age Limits: Min: 18 Years

Accepts Healthy Volunteers: No

Anticipated Start Date: July, 2003

Trial Registration Date: 06/24/2005

Date Last Updated: 07/15/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Strasbourg, France, 67091
Telephone: 973-235-5000 or 800-526-6367

  

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 21, 2008 at 2:35:50 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA